Journal article
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
The lancet oncology, Vol.22(4), pp.538-547
04/2021
DOI: 10.1016/S1470-2045(20)30753-1
PMID: 33794207
Abstract
The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT.
EMBRACE-I was a prospective, observational, multicentre cohort study. Data from patients from 24 centres in Europe, Asia, and North America were prospectively collected. The inclusion criteria were patients older than 18 years, with biopsy-proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, The International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA disease or FIGO stage IVB disease restricted to paraaortic lymph metastasis below the L1-L2 interspace, suitable for curative treatment. Treatment consisted of chemoradiotherapy (weekly intravenous cisplatin 40 mg/m
, 5-6 cycles, 1 day per cycle, plus 45-50 Gy external-beam radiotherapy delivered in 1·8-2 Gy fractions) followed by MRI-based IGABT. The MRI-based IGABT target volume definition and dose reporting was according to Groupe Européen de Curiethérapie European Society for Radiation Oncology recommendations. IGABT dose prescription was open according to institutional practice. Local control and late morbidity were selected as primary endpoints in all patients available for analysis. The study was registered with ClinicalTrials.gov, NCT00920920.
Patient accrual began on July 30, 2008, and closed on Dec 29, 2015. A total of 1416 patients were registered in the database. After exclusion for not meeting patient selection criteria before treatment, being registered but not entered in the database, meeting the exclusion criteria, and being falsely excluded, data from 1341 patients were available for analysis of disease and data from 1251 patients were available for assessment of morbidity outcome. MRI-based IGABT including dose optimisation was done in 1317 (98·2%) of 1341 patients. Median high-risk clinical target volume was 28 cm
(IQR 20-40) and median minimal dose to 90% of the clinical target volume (D
) was 90 Gy (IQR 85-94) equi-effective dose in 2 Gy per fraction. At a median follow-up of 51 months (IQR 20-64), actuarial overall 5-year local control was 92% (95% CI 90-93). Actuarial cumulative 5-year incidence of grade 3-5 morbidity was 6·8% (95% CI 5·4-8·6) for genitourinary events, 8·5% (6·9-10·6) for gastrointestinal events, 5·7% (4·3-7·6) for vaginal events, and 3·2% (2·2-4·5) for fistulae.
Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies.
Medical University of Vienna, Aarhus University Hospital, Elekta AB, and Varian Medical Systems.
Details
- Title: Subtitle
- MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
- Creators
- Richard Pötter - Medical University of ViennaKari Tanderup - Aarhus University HospitalMaximilian Paul Schmid - Medical University of ViennaIna Jürgenliemk-Schulz - University Medical Center UtrechtChristine Haie-Meder - Institut Gustave RoussyLars Ulrik Fokdal - Aarhus University HospitalAlina Emiliana Sturdza - Medical University of ViennaPeter Hoskin - University of ManchesterUmesh Mahantshetty - Homi Bhabha National InstituteBarbara Segedin - Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, SloveniaKjersti Bruheim - Oslo University HospitalFleur Huang - University of AlbertaBhavana Rai - Post Graduate Institute of Medical Education and ResearchRachel Cooper - St James's University HospitalElzbieta van der Steen-Banasik - Department of Radiotherapy, Radiotherapiegroep Arnhem, Arnhem, NetherlandsErik Van Limbergen - KU LeuvenBradley Rumwell Pieters - University of AmsterdamLi-Tee Tan - University of CambridgeRemi Abubakar Nout - Erasmus University RotterdamAstrid Agatha Catharina De Leeuw - Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, NetherlandsRobin Ristl - Medical University of ViennaPrimoz Petric - Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, SloveniaNicole Nesvacil - Medical University of ViennaKathrin Kirchheiner - Medical University of ViennaChristian Kirisits - Medical University of ViennaJacob Christian Lindegaard - Aarhus University HospitalEMBRACE Collaborative Group
- Contributors
- Yusung Kim (Contributor) - University of Iowa, Radiation Oncology
- Resource Type
- Journal article
- Publication Details
- The lancet oncology, Vol.22(4), pp.538-547
- DOI
- 10.1016/S1470-2045(20)30753-1
- PMID
- 33794207
- ISSN
- 1470-2045
- eISSN
- 1474-5488
- Grant note
- DOI: 10.13039/100007210, name: Varian Medical Systems; DOI: 10.13039/501100005788, name: Medizinische Universität Wien; DOI: 10.13039/100007606, name: Aarhus Universitetshospital; DOI: 10.13039/100011676, name: Elekta
- Language
- English
- Date published
- 04/2021
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984312961102771
Metrics
7 Record Views